XO1

About:

XO1 Ltd is a virtual biotechnology company formed specifically to develop ichorcumab.

Twitter/X: XO1pharma

Top Investors: Index Ventures, Limburgse Reconversie Maatschappij

Description:

XO1 Ltd is a biotechnology companied formed specifically to develop ichorcumab. It is a virtual company, with no offices or laboratory space, and operates by engaging high quality contract research and development specialists in Europe and the US, managed by a small team of experienced drug developers. Properly managed, virtual drug development not only controls costs but maximizes quality through flexible selection of the most appropriate supplier for each individual task. Read more: XO1 Ltd raises $11 million from Index Ventures to develop the 'holy grail' of anticoagulant drugs - FierceBiotech http://www.fiercebiotech.com/press-releases/xo1-ltd-raises-11-million-index-ventures-develop-holy-grail-anticoagulant-d#ixzz2WSG7D0Bu Subscribe at FierceBiotech

Total Funding Amount:

$11M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Hatfield, Hertford, United Kingdom

Founded Date:

2013-04-01

Contact Email:

webmaster(AT)xo1.co.uk

Founders:

David Grainger, Jim Huntington, Trevor Baglin

Number of Employees:

1-10

Last Funding Date:

2013-06-17

IPO Status:

Private

Industries: